Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;19(5):603-7.
doi: 10.1038/nm.3127. Epub 2013 Mar 31.

Targeting the Endocannabinoid System in the Treatment of Fragile X Syndrome


Targeting the Endocannabinoid System in the Treatment of Fragile X Syndrome

Arnau Busquets-Garcia et al. Nat Med. .


Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. The Fmr1 knockout model recapitulates the main traits of the disease. Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) signaling seem crucial in the pathology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS. The cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) are activated by phospholipid-derived endocannabinoids, and CB1R-driven long-term regulation of synaptic strength, as a consequence of mGluR5 activation, is altered in several brain areas of Fmr1 knockout mice. We found that CB1R blockade in male Fmr1 knockout (Fmr1(-/y)) mice through pharmacological and genetic approaches normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivated mTOR signaling and altered spine morphology, whereas pharmacological blockade of CB2R normalized anxiolytic-like behavior. Some of these traits were also reversed by pharmacological inhibition of mTOR or mGluR5. Thus, blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS.

Similar articles

See all similar articles

Cited by 71 articles

See all "Cited by" articles


    1. Neuron. 2012 Oct 18;76(2):325-37 - PubMed
    1. Physiol Rev. 2009 Jan;89(1):309-80 - PubMed
    1. Neuroscience. 2001;103(4):1043-50 - PubMed
    1. Neuron. 2012 Apr 12;74(1):49-56 - PubMed
    1. Sci Transl Med. 2012 Sep 19;4(152):152ra128 - PubMed

Publication types